{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:01:55Z","timestamp":1788454915446,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04558-5","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:01:50Z","timestamp":1785229310000},"page":"3048-3059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1\/2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0636","authenticated-orcid":false,"given":"Shabir A.","family":"Madhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasra","family":"Snaggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Skogeby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5327-1734","authenticated-orcid":false,"given":"Lee","family":"Fairlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Radley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Qing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C.","family":"Silmon de Monerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Gaylord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8421-828X","authenticated-orcid":false,"given":"Iona","family":"Munjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"4558_CR1","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.jmb.2019.01.035","volume":"431","author":"B Armistead","year":"2019","unstructured":"Armistead, B., Oler, E., Adams Waldorf, K. & Rajagopal, L. The double life of group B Streptococcus: asymptomatic colonizer and potent pathogen. J. Mol. Biol. 431, 2914\u20132931 (2019).","journal-title":"J. Mol. Biol."},{"key":"4558_CR2","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2214-109X(22)00093-6","volume":"10","author":"BP Gon\u00e7alves","year":"2022","unstructured":"Gon\u00e7alves, B. P. et al. Group B Streptococcus infection during pregnancy and infancy: estimates of regional and global burden. Lancet Glob. Health 10, e807\u2013e819 (2022).","journal-title":"Lancet Glob. Health"},{"key":"4558_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MOP.0000000000001223","volume":"35","author":"P Paul","year":"2023","unstructured":"Paul, P., Gon\u00e7alves, B. P., Le Doare, K. & Lawn, J. E. 20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention. Curr. Opin. Pediatr. 35, 223\u2013230 (2023).","journal-title":"Curr. Opin. Pediatr."},{"key":"4558_CR4","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1093\/cid\/cix658","volume":"65","author":"NJ Russell","year":"2017","unstructured":"Russell, N. J. et al. Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin. Infect. Dis. 65, S100\u2013S111 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"4558_CR5","doi-asserted-by":"publisher","unstructured":"Raabe, V. N. & Shane, A. L. Group B Streptococcus (Streptococcus agalactiae). Microbiol. Spectr. 7, https:\/\/doi.org\/10.1128\/microbiolspec.gpp3-0007-2018 (2019).","DOI":"10.1128\/microbiolspec.gpp3-0007-2018"},{"key":"4558_CR6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1881","volume":"144","author":"KM Puopolo","year":"2019","unstructured":"Puopolo, K. M., Lynfield, R. & Cummings, J. J. Management of infants at risk for group B streptococcal disease. Pediatrics 144, e20191881 (2019).","journal-title":"Pediatrics"},{"key":"4558_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00079-21","volume":"35","author":"T Tavares","year":"2022","unstructured":"Tavares, T., Pinho, L. & Bonifacio Andrade, E. Group B streptococcal neonatal meningitis. Clin, Microbiol. Rev. 35, e0007921 (2022).","journal-title":"Clin, Microbiol. Rev."},{"key":"4558_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(11)61651-6","volume":"379","author":"KM Edmond","year":"2012","unstructured":"Edmond, K. M. et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379, 547\u2013556 (2012).","journal-title":"Lancet"},{"key":"4558_CR9","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1093\/cid\/cix656","volume":"65","author":"L Madrid","year":"2017","unstructured":"Madrid, L. et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin. Infect. Dis. 65, S160\u2013S172 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"4558_CR10","doi-asserted-by":"publisher","first-page":"100897","DOI":"10.1016\/S2666-5247(24)00129-0","volume":"5","author":"G Kwatra","year":"2024","unstructured":"Kwatra, G. et al. Prevalence of group B Streptococcus colonisation in mother-newborn dyads in low-income and middle-income South Asian and African countries: a prospective, observational study. Lancet Microbe 5, 100897 (2024).","journal-title":"Lancet Microbe"},{"key":"4558_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/infdis\/jiz062","volume":"220","author":"ET Buurman","year":"2019","unstructured":"Buurman, E. T. et al. A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B Streptococcal infections by maternal immunization. J. Infect. Dis. 220, 105\u2013115 (2019).","journal-title":"J. Infect. Dis."},{"key":"4558_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102748","volume":"74","author":"TJR Panneflek","year":"2024","unstructured":"Panneflek, T. J. R. et al. Intrapartum antibiotic prophylaxis to prevent Group B streptococcal infections in newborn infants: a systematic review and meta-analysis comparing various strategies. EClinicalMedicine 74, 102748 (2024).","journal-title":"EClinicalMedicine"},{"key":"4558_CR13","first-page":"374","volume":"8","author":"S Li","year":"2017","unstructured":"Li, S. et al. Antibiotic prevention for maternal group B streptococcal colonization on neonatal GBS-related adverse outcomes: a meta-analysis. Front. Microbiol. 8, 374 (2017).","journal-title":"Front. Microbiol."},{"key":"4558_CR14","first-page":"1","volume":"59","author":"JR Verani","year":"2010","unstructured":"Verani, J. R., McGee, L. & Schrag, S. J. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm. Rep. 59, 1\u201336 (2010).","journal-title":"MMWR Recomm. Rep."},{"key":"4558_CR15","volume":"9","author":"F Miselli","year":"2022","unstructured":"Miselli, F. et al. Transmission of Group B streptococcus in late-onset neonatal disease: a narrative review of current evidence. Ther. Adv. Infect. Dis. 9, 20499361221142732 (2022).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"4558_CR16","doi-asserted-by":"publisher","first-page":"D20","DOI":"10.1016\/j.vaccine.2012.11.056","volume":"31","author":"SJ Schrag","year":"2013","unstructured":"Schrag, S. J. & Verani, J. R. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 31, D20\u2013D26 (2013).","journal-title":"Vaccine"},{"key":"4558_CR17","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1093\/cid\/cix654","volume":"65","author":"K Le Doare","year":"2017","unstructured":"Le Doare, K. et al. Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review. Clin. Infect. Dis. 65, S143\u2013S151 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"4558_CR18","doi-asserted-by":"crossref","unstructured":"Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee opinion, number 797. Obstet. Gynecol. 135, e51\u2212e72 (2020).","DOI":"10.1097\/AOG.0000000000003668"},{"key":"4558_CR19","unstructured":"UK National Screening Committe. Antenatal screening programme: Group B streptococcus. https:\/\/view-health-screening-recommendations.service.gov.uk\/group-b-streptococcus\/"},{"key":"4558_CR20","unstructured":"Management of Women with Group B Streptococcal (GBS) during Pregnancy. https:\/\/wisdom.nhs.wales\/health-board-guidelines\/swansea-bay-maternity-file\/policy-for-management-of-women-with-group-b-streptococcus-during-pregnancy\/#:~:text=3.1%20GBS%20Carrier%20Screening%20Recommendation,immune%20development%20and%20later%20allergy (NHS Wales, 2021)."},{"key":"4558_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.638871","volume":"9","author":"B Cinicola","year":"2021","unstructured":"Cinicola, B. et al. The protective role of maternal immunization in early life. Front. Pediatr. 9, 638871 (2021).","journal-title":"Front. Pediatr."},{"key":"4558_CR22","doi-asserted-by":"publisher","first-page":"7890","DOI":"10.1080\/14767058.2021.1937991","volume":"35","author":"E Brillo","year":"2022","unstructured":"Brillo, E., Tosto, V., Gerli, S. & Buonomo, E. COVID-19 vaccination in pregnancy and postpartum. J. Matern. Fetal Neonatal Med. 35, 7890\u20137910 (2022).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"4558_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41577-025-01162-5","volume":"25","author":"V Male","year":"2025","unstructured":"Male, V. & Jones, C. E. Vaccination in pregnancy to protect the newborn. Nat. Rev. Immunol. 25, 649\u2013661 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"4558_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cmi.2025.03.014","volume":"31","author":"H Kildegaard","year":"2025","unstructured":"Kildegaard, H. et al. Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019\u20132023. Clin. Microbiol. Infect. 31, 995\u20131002 (2025).","journal-title":"Clin. Microbiol. Infect."},{"key":"4558_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ogc.2023.02.003","volume":"50","author":"KE Fleming-Dutra","year":"2023","unstructured":"Fleming-Dutra, K. E. et al. Safety and effectiveness of maternal COVID-19 vaccines among pregnant people and infants. Obstet. Gynecol. Clin. North Am. 50, 279\u2013297 (2023).","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"4558_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","volume":"145","author":"EAF Sim\u00f5es","year":"2025","unstructured":"Sim\u00f5es, E. A. F. et al. Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial. Obstet. Gynecol. 145, 157\u2013167 (2025).","journal-title":"Obstet. Gynecol."},{"key":"4558_CR27","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/S1473-3099(18)30659-5","volume":"19","author":"K Le Doare","year":"2019","unstructured":"Le Doare, K. et al. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect. Dis. 19, e162\u2013e171 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"4558_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2037350","volume":"18","author":"J Absalon","year":"2022","unstructured":"Absalon, J. et al. Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. Hum. Vaccin. Immunother. 18, 2037350 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"4558_CR29","doi-asserted-by":"publisher","first-page":"127575","DOI":"10.1016\/j.vaccine.2025.127575","volume":"62","author":"N Thorn","year":"2025","unstructured":"Thorn, N., Karampatsas, K., Le Doare, K. & Heath, P. T. Progress towards a Group B streptococcal vaccine \u2212 where are we now? Vaccine 62, 127575 (2025).","journal-title":"Vaccine"},{"key":"4558_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64324-y","volume":"16","author":"JC Rhodes","year":"2025","unstructured":"Rhodes, J. C. et al. A US case-control study to estimate infant group B Streptococcal disease serological thresholds of risk-reduction. Nat. Commun. 16, 9381 (2025).","journal-title":"Nat. Commun."},{"key":"4558_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1473-3099(20)30478-3","volume":"21","author":"J Absalon","year":"2021","unstructured":"Absalon, J. et al. Safety and immunogenicity of a novel hexavalent group B Streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1\/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. Lancet Infect. Dis. 21, 263\u2013274 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"4558_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa2116045","volume":"389","author":"SA Madhi","year":"2023","unstructured":"Madhi, S. A. et al. Potential for maternally administered vaccine for infant group B Streptococcus. N. Engl. J. Med. 389, 215\u2013227 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4558_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2311480","volume":"20","author":"MA Gaylord","year":"2024","unstructured":"Gaylord, M. A. et al. Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B Streptococcus capsular polysaccharides. Hum. Vaccin. Immunother. 20, 2311480 (2024).","journal-title":"Hum. Vaccin. Immunother."},{"key":"4558_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S2666-5247(24)00038-7","volume":"5","author":"A Saukkoriipi","year":"2024","unstructured":"Saukkoriipi, A. et al. Association between anti-capsular IgG levels at birth and risk of invasive group B Streptococcus disease in Finnish newborns: a retrospective case-control study. Lancet Microbe 5, 689\u2013696 (2024).","journal-title":"Lancet Microbe"},{"key":"4558_CR35","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S1473-3099(25)00216-6","volume":"25","author":"B Jongihlati","year":"2025","unstructured":"Jongihlati, B. et al. Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1\/2 randomised controlled trial. Lancet Infect. Dis. 25, 1138\u20131148 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"4558_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae220","volume":"11","author":"K Feemster","year":"2024","unstructured":"Feemster, K. et al. Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities. Open Forum Infect. Dis. 11, ofae220 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"4558_CR37","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/microorganisms8101521","volume":"8","author":"M Pizza","year":"2020","unstructured":"Pizza, M., Bekkat-Berkani, R. & Rappuoli, R. Vaccines against meningococcal diseases. Microorganisms 8, 1521 (2020).","journal-title":"Microorganisms"},{"key":"4558_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/vaccines13010019","volume":"13","author":"P Cruz","year":"2024","unstructured":"Cruz, P. et al. Immunobridging trials: an important tool to protect vulnerable and immunocompromised patients against evolving pathogens. Vaccines (Basel) 13, 19 (2024).","journal-title":"Vaccines (Basel)"},{"key":"4558_CR39","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451\u20131464 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4558_CR40","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1093\/infdis\/jiaf096","volume":"231","author":"WB Smith","year":"2025","unstructured":"Smith, W. B. et al. A phase 2b trial evaluating the safety, tolerability, and immunogenicity of a 6-valent group B Streptococcus vaccine administered concomitantly with tetanus, diphtheria, and acellular pertussis vaccine in healthy nonpregnant female individuals. J. Infect. Dis. 231, e1065\u2013e1074 (2025).","journal-title":"J. Infect. Dis."},{"key":"4558_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1473-3099(13)70332-3","volume":"14","author":"IO Okike","year":"2014","unstructured":"Okike, I. O. et al. Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004\u221211: an observational study. Lancet Infect. Dis. 14, 301\u2013307 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"4558_CR42","first-page":"101120","volume":"47","author":"N Prasad","year":"2025","unstructured":"Prasad, N. et al. The epidemiology of bacterial meningitis in the United States during 2008\u22122023: an analysis of active, laboratory, population-based, multistate surveillance data. Lancet Reg. Health Am. 47, 101120 (2025).","journal-title":"Lancet Reg. Health Am."},{"key":"4558_CR43","unstructured":"Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. https:\/\/www.fda.gov\/media\/73679\/download (US Food and Drug Administration, 2007)."},{"key":"4558_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00667-1","volume":"8","author":"A Esadze","year":"2023","unstructured":"Esadze, A. et al. Calibration of a serum reference standard for Group B streptococcal polysaccharide conjugate vaccine development using surface plasmon resonance. NPJ Vaccines 8, 71 (2023).","journal-title":"NPJ Vaccines"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04558-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04558-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:01:28Z","timestamp":1786629688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04558-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4558"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04558-5","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.A.M. received funding from Pfizer (to his institution) as an investigator for this study and received funding on GBS research from the Gates Foundation, Minervax and Inventprise (to his institution) and non-GBS grant funds from Merck, the Gates Foundation and GlaxoSmithKline (to his institution). S.B. received funding from Pfizer (to his institution) as an investigator for this study and received non-GBS funding from Merck, Sanofi and GlaxoSmithKline (to his institution). J.B. received funding from Pfizer (to his institution) as an investigator for this study. L.F. received funding from Pfizer (to her institution) as an investigator for this study and received funding for GBS research from Minervax (to her institution). All other authors are current or former employees of Pfizer Inc and may hold stock or stock options.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}